CIP2A and prostate cancer: The G84E variant showed a strong interaction with a CIP2A polymorphism in dual carriers; the OR for prostate cancer was 21.1 and the interaction was replicated in another Finnish cohort and with a lower risk in a Swedish population (OR 6.4) [15].